Summary:
In adults with type 2 diabetes treated with basal insulin, continuous glucose monitoring (CGM) significantly improved glycemic management with substantial HbA1c reduction over 3 months
compared to blood glucose monitoring (BGM), though it was associated with potential device-related discomfort and adherence challenges.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes inadequately controlled on basal insulin therapy. |
| Intervention | Use of continuous glucose monitoring (CGM) for glycemic management over a 3-month period. |
| Comparison | Standard blood glucose monitoring (BGM) as commonly practiced in basal insulin-treated type 2 diabetes. |
| Outcome | CGM use led to rapid and significant reduction in HbA1c within 3 months compared to BGM, indicating improved glycemic control; associated side effects included possible device-related discomfort and adherence issues. |
Source: Martens, Thomas W, et al. “Rapid improvements in glycemic management with use of continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin: 3-month analysis of the MOBILE study.” Read article here.
